FDA Halts Enrollment in Mersana ' s Cancer Drug Studies FDA Halts Enrollment in Mersana ' s Cancer Drug Studies
Mersana Therapeutics said on Thursday the FDA had paused enrollment in two studies of its ovarian cancer drug after five deaths in bleeding-related events.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Bleeding | Cancer | Cancer & Oncology | Health | Hematology | Ovarian Cancer | Ovaries | Study